<DOC>
	<DOCNO>NCT00844649</DOCNO>
	<brief_summary>Phase III Metastatic Pancreatic Cancer</brief_summary>
	<brief_title>Phase III Study ABI-007 ( Albumin-bound Paclitaxel ) Plus Gemcitabine Versus Gemcitabine Metastatic Adenocarcinoma Pancreas</brief_title>
	<detailed_description>A Phase III , open-label randomize , multicenter trial compare ABI-007 ( Albumin-bound Paclitaxel ) combination gemcitabine administer weekly standard treatment ( gemcitabine monotherapy ) respect overall survival , objective tumor response rate Progression Free Survival ( PFS ) patient diagnose metastatic adenocarcinoma pancreas .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Inclusion Criteria A participant eligible inclusion study follow criterion meet : 1 . Participant definitive histologically cytologically confirm metastatic adenocarcinoma pancreas . The definitive diagnosis metastatic pancreatic adenocarcinoma make integrate histopathological data within context clinical radiographic data . Participants islet cell neoplasms exclude . 2 . Initial diagnosis metastatic disease must occur ≤6 week prior randomization study . 3 . Patient one metastatic tumor measurable Computed Tomography ( CT ) scan Magnetic resonance imaging ( MRI ) , patient allergic CT contrast medium ) . 4 . Male nonpregnant nonlactating female , ≥ 18 year age . If female patient childbearing potential , evidence regular menstrual period , must negative serum pregnancy test BetaHuman Chorionic Gonadotropin ( βhCG ) document 72 hour prior first administration study drug . If sexually active , patient must agree use contraception consider adequate appropriate Investigator period administration study drug . In addition , male female patient must utilize contraception end treatment recommend product 's Summary Product Characteristics Prescribing Information provide study manual . 5 . Patients must receive previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic disease . Prior treatment 5Fluorouracil ( 5FU ) gemcitabine administer radiation sensitizer adjuvant setting allow , provide least 6 month elapse since completion last dose linger toxicity present . Patients receive cytotoxic dos gemcitabine chemotherapy adjuvant set eligible study . 6 . Patient adequate biological parameter demonstrate follow blood count Baseline ( obtain ≤14 day prior randomization ) : Absolute neutrophil count ( ANC ) ≥ 1.5 × 10^9/L ; Platelet count ≥ 100,000/mm^3 ( 100 × 10^9/L ) ; Hemoglobin ( Hgb ) ≥ 9 g/dL . 7 . Patient follow blood chemistry level Baseline ( obtain ≤14 day prior randomization ) : Aspartate Transaminase ( AST ) , Serum GlutamicOxaloacetic Transaminase ( SGOT ) , Alanine Transaminase ( ALT ) Serum GlutamicPyruvic Transaminase ( SGPT ) ≤ 2.5 × upper limit normal range ( ULN ) , unless liver metastases clearly present , ≤ 5 × ULN allow Total bilirubin ≤ ULN Serum creatinine within normal limit calculate clearance ≥ 60 mL/min/1.73 m^2 patient serum creatinine level institutional normal value . If use creatinine clearance , actual body weight used calculate creatinine clearance ( e.g. , use CockroftGault formula ) . For patient Body Mass Index ( BMI ) &gt; 30 kg/m^2 , lean body weight use instead . 8 . Patient acceptable coagulation study ( obtain ≤14 day prior randomization ) demonstrate prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit ( ± 15 % ) . 9 . Patient clinically significant abnormality urinalysis result ( obtained ≤14 day prior randomization ) . 10 . Patient Karnofsky performance status ( KPS ) ≥ 70 . Two observer require assess KPS . If discrepant , one low assessment consider true . 11 . Patients asymptomatic jaundice prior Day 1 . Significant symptomatic amount ascites drain prior Day 1 . Pain symptom stable require modification analgesic management prior Day 1 . 12 . Patient informed nature study , agree participate study , sign Informed Consent Form ( ICF ) prior participation studyrelated activity . Exclusion Criteria A patient eligible inclusion study follow criterion apply : 1 . Patient known brain metastasis , unless previously treat wellcontrolled least 3 month ( define clinically stable , edema , steroid stable 2 scan least 4 week apart ) . 2 . Patient locally advance disease . 3 . Patient experience ≥10 % decrease KPS baseline visit within 72 hour prior randomization . 4 . Patient ≥20 % decrease serum albumin level baseline visit within 72 hour prior randomization . 5 . History malignancy last 5 year . Patients prior history situ cancer basal squamous cell skin cancer eligible . Patients malignancy eligible cured surgery alone surgery plus radiotherapy continuously diseasefree least 5 year . 6 . Patient use Coumadin . 7 . Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 8 . Patient known historical active infection Human Immunodeficiency Virus ( HIV ) , hepatitis B , hepatitis C. 9 . Patient undergone major surgery , diagnostic surgery ( i.e.surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 10 . Patient history allergy hypersensitivity study drug excipients , patient exhibit event outline Contraindications Special Warnings Precautions section product comparator Summary Product Characteristics ( SmPC ) Prescribing Information . 11 . History connective tissue disorder ( e.g. , lupus , scleroderma , arteritis nodosa ) . 12 . Patients history interstitial lung disease . 13 . History chronic leukemia ( e.g. , chronic lymphocytic leukemia ) . 14 . Patients high cardiovascular risk , include , limited , recent coronary stenting myocardial infarction past year . 15 . History Peripheral Artery Disease ( e.g , . claudication , Leo Buerger 's disease ) . 16 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 17 . Patient enrol clinical protocol investigational trial . 18 . Patient unwilling unable comply study procedure , plan take vacation 7 consecutive day course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>